Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen for Macular Edema Secondary to BRVO
NCT00406107Phase 4Completed
- Sponsor
- Palmetto Retina Center
- Start
- Jan 2006
- Primary completion
- Dec 2007
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegaptanib sodium in branch retinal vein occlusion (BRVO) and macular edema (2 arms), sponsored by Palmetto Retina Center. Primary endpoint: Change in ETDRS Best Corrected Visual Acuity at 54 weeks. Started Jan 2006; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on NCT00406107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406107.